Protection of vaccine immunity by inhibiting Fas/FasL signaling

通过抑制 Fas/FasL 信号传导保护疫苗免疫力

基本信息

  • 批准号:
    7853033
  • 负责人:
  • 金额:
    $ 49.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-29 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Lymphocytes bearing high levels of FasL are known to suppress cell-mediated immunity and destroy the efficacy of DNA vaccines. Their ability to kill the antigen-presenting cells can be eliminated by several different mechanisms and we are exploring a number of these mechanisms to find one optimal for promoting cell- mediated responses to SIVGag vaccination. It is our hypothesis that treatment with small molecules that block Fas/FasL signaling could prevent the destruction of antigen-presenting-cells (APC), and allow the development of vigorous anti-retroviral immunity. High levels of CD4+FasL+ cells during AIDS also reduce immunity against opportunistic infections and neoplastic events. Therefore, treatments to block signals delivered by these cells could boost resistance to opportunistic infections and to AIDS-associated cancers. The experimental plan is to develop novel small-molecule inhibitors of Fas/FasL signaling to prevent APC lysis after vaccination. We identified three different strategies for Fas/FasL inhibition which will be compared in mouse immunization studies to identify the strategy, or combination of strategies, most suitable for promoting cell-mediated immunity to a common SIV vaccine antigen, p27Gag. Among our approaches we are investigating the use of pre-ligand assembly domains (PLAD) that are critical for function in TNF receptor superfamily proteins. PLAD represent a novel class of TNF and Fas receptor inhibitors with important advantages for use during DNA vaccination and prime-boost strategies. We propose structural biology studies to address key questions about PLAD structural/functional elements critical for inhibiting Fas/FasL. Our studies will compare inhibitors of FasL signaling that should have short-term effects and highly-specific targets, yet should not interfere with the development of strong functional responses to vaccine antigens PUBLIC HEALTH RELEVANCE: People with AIDS carry a subset of white blood cells that destroy their ability to fight opportunistic infections and to prevent cancer. Attempts to fix this problem with long-lasting solutions would endanger the normal balance of blood cells. Our studies propose to test inhibitors of cell-death signals that would have short-term effects and highly-specific targets, yet would not interfere with the development of strong responses against cancers or infections.
描述(由申请方提供):已知携带高水平FasL的淋巴细胞可抑制细胞介导的免疫并破坏DNA疫苗的效力。它们杀死抗原呈递细胞的能力可以通过几种不同的机制消除,并且我们正在探索许多这些机制以找到一种促进细胞介导的对SIVGag疫苗接种的应答的最佳机制。我们的假设是,用阻断Fas/FasL信号传导的小分子治疗可以防止抗原呈递细胞(APC)的破坏,并允许产生强有力的抗逆转录病毒免疫。AIDS期间高水平的CD 4 +FasL+细胞也降低了对机会性感染和肿瘤事件的免疫力。因此,阻断这些细胞传递信号的治疗方法可以提高对机会性感染和艾滋病相关癌症的抵抗力。实验计划是开发新的Fas/FasL信号传导的小分子抑制剂,以防止疫苗接种后APC裂解。我们确定了三种不同的Fas/FasL抑制策略,将在小鼠免疫研究中进行比较,以确定最适合促进对常见SIV疫苗抗原p27 Gag的细胞介导免疫的策略或策略组合。在我们的方法中,我们正在研究使用前配体组装结构域(PLAD),这对TNF受体超家族蛋白的功能至关重要。PLAD代表一类新型TNF和Fas受体抑制剂,其在DNA疫苗接种和初免-加强策略期间具有重要优势。我们建议结构生物学研究,以解决关键问题的PLAD结构/功能元件抑制Fas/FasL的关键。我们的研究将比较FasL信号传导抑制剂,这些抑制剂应该具有短期效应和高度特异性靶点,但不应该干扰对疫苗抗原的强烈功能反应的发展。 公共卫生关系:艾滋病患者携带一种白色血细胞,这种细胞破坏了他们抵抗机会性感染和预防癌症的能力。试图用持久的解决方案来解决这个问题会危及血细胞的正常平衡。我们的研究旨在测试细胞死亡信号的抑制剂,这些抑制剂具有短期效应和高度特异性的靶点,但不会干扰对癌症或感染的强烈反应的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maria S. Salvato其他文献

Taxonomy of the order Bunyavirales: second update 2018
  • DOI:
    10.1007/s00705-018-04127-3
  • 发表时间:
    2019-01-20
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Piet Maes;Scott Adkins;Sergey V. Alkhovsky;Tatjana Avšič-Županc;Matthew J. Ballinger;Dennis A. Bente;Martin Beer;Éric Bergeron;Carol D. Blair;Thomas Briese;Michael J. Buchmeier;Felicity J. Burt;Charles H. Calisher;Rémi N. Charrel;Il Ryong Choi;J. Christopher S. Clegg;Juan Carlos de la Torre;Xavier de Lamballerie;Joseph L. DeRisi;Michele Digiaro;Mike Drebot;Hideki Ebihara;Toufic Elbeaino;Koray Ergünay;Charles F. Fulhorst;Aura R. Garrison;George Fú Gāo;Jean-Paul J. Gonzalez;Martin H. Groschup;Stephan Günther;Anne-Lise Haenni;Roy A. Hall;Roger Hewson;Holly R. Hughes;Rakesh K. Jain;Miranda Gilda Jonson;Sandra Junglen;Boris Klempa;Jonas Klingström;Richard Kormelink;Amy J. Lambert;Stanley A. Langevin;Igor S. Lukashevich;Marco Marklewitz;Giovanni P. Martelli;Nicole Mielke-Ehret;Ali Mirazimi;Hans-Peter Mühlbach;Rayapati Naidu;Márcio Roberto Teixeira Nunes;Gustavo Palacios;Anna Papa;Janusz T. Pawęska;Clarence J. Peters;Alexander Plyusnin;Sheli R. Radoshitzky;Renato O. Resende;Víctor Romanowski;Amadou Alpha Sall;Maria S. Salvato;Takahide Sasaya;Connie Schmaljohn;Xiǎohóng Shí;Yukio Shirako;Peter Simmonds;Manuela Sironi;Jin-Won Song;Jessica R. Spengler;Mark D. Stenglein;Robert B. Tesh;Massimo Turina;Tàiyún Wèi;Anna E. Whitfield;Shyi-Dong Yeh;F. Murilo Zerbini;Yong-Zhen Zhang;Xueping Zhou;Jens H. Kuhn
  • 通讯作者:
    Jens H. Kuhn
2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales
  • DOI:
    10.1007/s00705-020-04731-2
  • 发表时间:
    2020-09-04
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Jens H. Kuhn;Scott Adkins;Daniela Alioto;Sergey V. Alkhovsky;Gaya K. Amarasinghe;Simon J. Anthony;Tatjana Avšič-Županc;María A. Ayllón;Justin Bahl;Anne Balkema-Buschmann;Matthew J. Ballinger;Tomáš Bartonička;Christopher Basler;Sina Bavari;Martin Beer;Dennis A. Bente;Éric Bergeron;Brian H. Bird;Carol Blair;Kim R. Blasdell;Steven B. Bradfute;Rachel Breyta;Thomas Briese;Paul A. Brown;Ursula J. Buchholz;Michael J. Buchmeier;Alexander Bukreyev;Felicity Burt;Nihal Buzkan;Charles H. Calisher;Mengji Cao;Inmaculada Casas;John Chamberlain;Kartik Chandran;Rémi N. Charrel;Biao Chen;Michela Chiumenti;Il-Ryong Choi;J. Christopher S. Clegg;Ian Crozier;John V. da Graça;Elena Dal Bó;Alberto M. R. Dávila;Juan Carlos de la Torre;Xavier de Lamballerie;Rik L. de Swart;Patrick L. Di Bello;Nicholas Di Paola;Francesco Di Serio;Ralf G. Dietzgen;Michele Digiaro;Valerian V. Dolja;Olga Dolnik;Michael A. Drebot;Jan Felix Drexler;Ralf Dürrwald;Lucie Dufkova;William G. Dundon;W. Paul Duprex;John M. Dye;Andrew J. Easton;Hideki Ebihara;Toufic Elbeaino;Koray Ergünay;Jorlan Fernandes;Anthony R. Fooks;Pierre B. H. Formenty;Leonie F. Forth;Ron A. M. Fouchier;Juliana Freitas-Astúa;Selma Gago-Zachert;George Fú Gāo;María Laura García;Adolfo García-Sastre;Aura R. Garrison;Aiah Gbakima;Tracey Goldstein;Jean-Paul J. Gonzalez;Anthony Griffiths;Martin H. Groschup;Stephan Günther;Alexandro Guterres;Roy A. Hall;John Hammond;Mohamed Hassan;Jussi Hepojoki;Satu Hepojoki;Udo Hetzel;Roger Hewson;Bernd Hoffmann;Seiji Hongo;Dirk Höper;Masayuki Horie;Holly R. Hughes;Timothy H. Hyndman;Amara Jambai;Rodrigo Jardim;Dàohóng Jiāng;Qi Jin;Gilda B. Jonson;Sandra Junglen;Serpil Karadağ;Karen E. Keller;Boris Klempa;Jonas Klingström;Gary Kobinger;Hideki Kondō;Eugene V. Koonin;Mart Krupovic;Gael Kurath;Ivan V. Kuzmin;Lies Laenen;Robert A. Lamb;Amy J. Lambert;Stanley L. Langevin;Benhur Lee;Elba R. S. Lemos;Eric M. Leroy;Dexin Li;Jiànróng Lǐ;Mifang Liang;Wénwén Liú;Yàn Liú;Igor S. Lukashevich;Piet Maes;William Marciel de Souza;Marco Marklewitz;Sergio H. Marshall;Giovanni P. Martelli;Robert R. Martin;Shin-Yi L. Marzano;Sébastien Massart;John W. McCauley;Nicole Mielke-Ehret;Angelantonio Minafra;Maria Minutolo;Ali Mirazimi;Hans-Peter Mühlbach;Elke Mühlberger;Rayapati Naidu;Tomohide Natsuaki;Beatriz Navarro;José A. Navarro;Sergey V. Netesov;Gabriele Neumann;Norbert Nowotny;Márcio R. T. Nunes;Are Nylund;Arnfinn L. Økland;Renata C. Oliveira;Gustavo Palacios;Vicente Pallas;Bernadett Pályi;Anna Papa;Colin R. Parrish;Alex Pauvolid-Corrêa;Janusz T. Pawęska;Susan Payne;Daniel R. Pérez;Florian Pfaff;Sheli R. Radoshitzky;Aziz-ul Rahman;Pedro L. Ramos-González;Renato O. Resende;Carina A. Reyes;Bertus K. Rima;Víctor Romanowski;Gabriel Robles Luna;Paul Rota;Dennis Rubbenstroth;Jonathan A. Runstadler;Daniel Ruzek;Sead Sabanadzovic;Jiří Salát;Amadou Alpha Sall;Maria S. Salvato;Kamil Sarpkaya;Takahide Sasaya;Martin Schwemmle;Muhammad Z. Shabbir;Xiǎohóng Shí;Zhènglì Shí;Yukio Shirako;Peter Simmonds;Jana Širmarová;Manuela Sironi;Sophie Smither;Teemu Smura;Jin-Won Song;Kirsten M. Spann;Jessica R. Spengler;Mark D. Stenglein;David M. Stone;Petra Straková;Ayato Takada;Robert B. Tesh;Natalie J. Thornburg;Keizō Tomonaga;Noël Tordo;Jonathan S. Towner;Massimo Turina;Ioannis Tzanetakis;Rainer G. Ulrich;Anna Maria Vaira;Bernadette van den Hoogen;Arvind Varsani;Nikos Vasilakis;Martin Verbeek;Victoria Wahl;Peter J. Walker;Hui Wang;Jianwei Wang;Xifeng Wang;Lin-Fa Wang;Tàiyún Wèi;Heather Wells;Anna E. Whitfield;John V. Williams;Yuri I. Wolf;Zhìqiáng Wú;Xin Yang;Xīnglóu Yáng;Xuejie Yu;Natalya Yutin;F. Murilo Zerbini;Tong Zhang;Yong-Zhen Zhang;Guohui Zhou;Xueping Zhou
  • 通讯作者:
    Xueping Zhou

Maria S. Salvato的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maria S. Salvato', 18)}}的其他基金

HIV Persistence and Cardiopulmonary Disease
艾滋病毒持续存在与心肺疾病
  • 批准号:
    9098781
  • 财政年份:
    2015
  • 资助金额:
    $ 49.28万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8880111
  • 财政年份:
    2012
  • 资助金额:
    $ 49.28万
  • 项目类别:
Protection of vaccine immunity by inhibiting Fas/FasL signaling
通过抑制 Fas/FasL 信号传导保护疫苗免疫力
  • 批准号:
    7944104
  • 财政年份:
    2009
  • 资助金额:
    $ 49.28万
  • 项目类别:
A Lassa Vaccine in primates with AIDS
用于患有艾滋病的灵长类动物的拉沙疫苗
  • 批准号:
    7914705
  • 财政年份:
    2009
  • 资助金额:
    $ 49.28万
  • 项目类别:
A Lassa Vaccine in primates with AIDS
用于患有艾滋病的灵长类动物的拉沙疫苗
  • 批准号:
    7532593
  • 财政年份:
    2008
  • 资助金额:
    $ 49.28万
  • 项目类别:
A Lassa Vaccine in primates with AIDS
用于患有艾滋病的灵长类动物的拉沙疫苗
  • 批准号:
    7646424
  • 财政年份:
    2008
  • 资助金额:
    $ 49.28万
  • 项目类别:
Recombinant Yellow Fever 17D-Lassa Vaccine
重组黄热病 17D 拉沙疫苗
  • 批准号:
    7617628
  • 财政年份:
    2007
  • 资助金额:
    $ 49.28万
  • 项目类别:
Dendritic Cell Targeting of Lassa Fever Vaccine
拉沙热疫苗的树突状细胞靶向
  • 批准号:
    6759564
  • 财政年份:
    2004
  • 资助金额:
    $ 49.28万
  • 项目类别:
Dendritic Cell Targeting of Lassa Fever Vaccine
拉沙热疫苗的树突状细胞靶向
  • 批准号:
    6953750
  • 财政年份:
    2004
  • 资助金额:
    $ 49.28万
  • 项目类别:
Non-Viral Delivery of DNA Vaccines to the Buccal Mucosa
DNA 疫苗非病毒递送至颊粘膜
  • 批准号:
    6652582
  • 财政年份:
    2002
  • 资助金额:
    $ 49.28万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 49.28万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 49.28万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 49.28万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 49.28万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 49.28万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 49.28万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 49.28万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 49.28万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 49.28万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 49.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了